Osteovile (Alfacalcidol)

Alfacalcidol, the active ingredient in Osteovile, is a vitamin D analog presented as a strength/form for oral use. It is used to manage disorders of calcium metabolism in patients with chronic kidney disease and other conditions affecting bone health.

GNH USA supplies Osteovile as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osteovile is a vitamin D analog that acts on calcium‑regulating pathways in several metabolic bone disorders. - Chronic kidney disease‑related mineral and bone disorder (CKD‑MBD): helps maintain serum calcium and phosphate balance. - Hypocalcemia associated with hypoparathyroidism: raises serum calcium levels. - Osteomalacia due to vitamin D deficiency: promotes bone mineralisation. - Secondary hyperparathyroidism: reduces parathyroid hormone secretion.

Adverse reactions to alfacalcidol are generally related to excess calcium or vitamin D activity.

Common Side Effects: - Hypercalcemia: elevated blood calcium levels. - Hyperphosphatemia: increased serum phosphate. - Nausea or vomiting. - Loss of appetite. - Headache. - Fatigue.

Serious or Rare Side Effects: - Nephrolithiasis: kidney stone formation. - Cardiac arrhythmias linked to severe hypercalcemia. - Calcific uremic arteriopathy. - Severe allergic reactions such as anaphylaxis. - Persistent hypercalcemia leading to renal impairment.

When prescribing alfacalcidol, clinicians should consider several safety aspects. - Monitor serum calcium and phosphate: regular laboratory testing is essential. - Adjust dose in renal impairment: reduced clearance may increase risk of toxicity. - Avoid use in patients with active granulomatous disease: risk of uncontrolled vitamin D activation. - Caution in hyperparathyroidism not related to CKD: may exacerbate calcium imbalance. - Pregnancy and lactation: only use if clearly needed, after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Alfacalcidol can interact with several medicines that influence calcium balance or vitamin D metabolism.

Major Interactions (Avoid): - Thiazide diuretics: may potentiate hypercalcemia. - Calcium supplements or calcium‑rich antacids: increase risk of excess calcium. - Vitamin K antagonists (e.g., warfarin): may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Anticonvulsants (phenytoin, phenobarbital): may increase metabolic clearance of alfacalcidol. - Corticosteroids: can reduce vitamin D activation. - Bisphosphonates: concurrent use may mask hypercalcemia signs.